Wall Street Zen Upgrades Lyell Immunopharma (NASDAQ:LYEL) to Hold

Lyell Immunopharma (NASDAQ:LYEL) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other equities analysts have also recently commented on LYEL. Stifel Nicolaus initiated coverage on Lyell Immunopharma in a report on Thursday, August 6th. They set a “buy” rating and a $36.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 price objective on the stock. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Finally, Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Price Performance

Shares of LYEL stock opened at $9.31 on Friday. The company has a fifty day moving average price of $11.36 and a two-hundred day moving average price of $17.17. Lyell Immunopharma has a one year low of $7.20 and a one year high of $45.00. The stock has a market cap of $228.09 million, a P/E ratio of -0.73 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.02. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. As a group, equities research analysts anticipate that Lyell Immunopharma will post -7.16 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

A number of hedge funds have recently modified their holdings of LYEL. Opaleye Management Inc. grew its stake in Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after buying an additional 264,928 shares during the last quarter. Squarepoint Ops LLC raised its holdings in Lyell Immunopharma by 119.4% in the 2nd quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after acquiring an additional 23,028 shares during the period. Velan Capital Investment Management LP raised its holdings in Lyell Immunopharma by 2.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after acquiring an additional 3,000 shares during the period. venBio Partners LLC bought a new position in Lyell Immunopharma in the 2nd quarter valued at about $4,744,643. Finally, Bank of New York Mellon Corp acquired a new stake in Lyell Immunopharma during the second quarter worth approximately $347,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.